REVIEW PERAN VAKSIN DEMAM TIFOID UNTUK WISATAWAN DI DAERAH TROPIS

Anna Lewi Santoso; Ayling Sanjaya; Jemima Lewi Santoso; Ibrahim Njoto

doi:10.62354/jurnalmedicare.v4i3.226

Authors

Anna Lewi Santoso Department of Histology, Faculty of Medicine, Wijaya Kusuma University, Surabaya
Ayling Sanjaya Department of Pediatrics, Faculty of Medicine, Wijaya Kusuma University, Surabaya
Jemima Lewi Santoso Department of Biomedicine, Faculty of Medicine, Ciputra University, Surabaya
Ibrahim Njoto Department of Anatomy, Faculty of Medicine, Wijaya Kusuma University, Surabaya

DOI:

https://doi.org/10.62354/jurnalmedicare.v4i3.226

Keywords:

trropical areas, typhoid fever, vaccination, travel;ers

Abstract

Typhoid fever is a systemic infectious disease caused by Salmonella enterica subspecies enterica serovar Typhi (S. Typhi). Transmission commonly occurs through food or drinks contaminated with the feces or urine of infected individuals. Travelers to endemic areas, particularly tropical regions, are at high risk of infection. Symptoms include high fever, nausea, and abdominal pain. Improvements in sanitation and hygiene have contributed to a decline in typhoid incidence; however, the effectiveness of antibiotic treatment is decreasing due to rising resistance. Vaccination has become a highly recommended preventive measure for both local populations and travelers. This study is a literature review of English-language articles published between 2014 and 2024, sourced from PubMed (106 articles), Google Scholar (915), and ProQuest (14), using the keywords “typhoid fever” and “vaccine.” A total of 49 relevant articles were analyzed. The results show that the World Health Organization (WHO) recommends typhoid vaccination in endemic areas. In conclusion, vaccination is effective in reducing morbidity and mortality rates and in preventing antibiotic resistance. Well-planned preventive strategies are essential for protecting public health.

Downloads

Download data is not yet available.

References

Amicizia, D. et al. (2019) ‘Burden of typhoid fever and cholera: Similarities and differences. Prevention strategies for European travelers to endemic/epidemic areas’, Journal of Preventive Medicine and Hygiene, 60(4), pp. E271–E285. doi: 10.15167/2421-4248/jpmh2019.60.4.1333.

Balasubramanian, R. et al. (2019) ‘The global burden and epidemiology of invasive non-typhoidal Salmonella infections’, Human Vaccines and Immunotherapeutics, 15(6), pp. 1421–1426. doi: 10.1080/21645515.2018.1504717.

Barton, A. J. et al. (2021) ‘Host restriction, pathogenesis and chronic carriage of typhoidal Salmonella’, FEMS Microbiology Reviews, 45(5), pp. 1–12. doi: 10.1093/femsre/fuab014.

Capeding, M. R. et al. (2018) ‘Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children’, Vaccine, 36(26), pp. 3794–3801. doi: 10.1016/j.vaccine.2018.05.038.

Capeding, M. R. et al. (2020) ‘Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report’, Vaccine, 38(28), pp. 4476–4483. doi: 10.1016/j.vaccine.2019.09.074.

Cartee, R. T. et al. (2020) ‘A phase 1 randomized safety, reactogenicity, and immunogenicity study of typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever’, PLoS Neglected Tropical Diseases, 14(1), pp. 1–15. doi: 10.1371/journal.pntd.0007912.

Darton, T. C. et al. (2016) ‘Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a’, PLoS Neglected Tropical Diseases, 10(8), pp. 1–27. doi: 10.1371/journal.pntd.0004926.

Gayetfile:///C:/Users/James/Documents/Atelier de recherche/Rotavirus_vaccines_past_present_and_futu.pdf (2017) ‘crossm Vaccination against Salmonella Infection ’:, Microbiology and Moleculer, Biologi Reviews, 81(3), pp. 1–26. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28615285.

Gessner, B. D., Halloran, M. E. and Khan, I. (2015) ‘The case for a typhoid vaccine probe study and overview of design elements’, Vaccine, 33(S3), pp. C30–C35. doi: 10.1016/j.vaccine.2015.03.085.

Gibani, M. M. et al. (2020) ‘Homologous and heterologous re-challenge with salmonella typhi and salmonella paratyphi a in a randomised controlled human infection model’, PLoS Neglected Tropical Diseases, 14(10), pp. 1–25. doi: 10.1371/journal.pntd.0008783.

Hajj Hussein, I. et al. (2015) ‘Vaccines Through Centuries: Major Cornerstones of Global Health’, Frontiers in Public Health, 3(November), pp. 1–16. doi: 10.3389/fpubh.2015.00269.

Jin, C. et al. (2017) ‘Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial’, The Lancet, 390(10111), pp. 2472–2480. doi: 10.1016/S0140-6736(17)32149-9.

Kariuki, S. et al. (2015) ‘Antimicrobial resistance and management of invasive Salmonella disease’, Vaccine, 33(S3), pp. C21–C29. doi: 10.1016/j.vaccine.2015.03.102.

Khan, M. I. et al. (2017) ‘Barriers to typhoid fever vaccine access in endemic countries’, Research and Reports in Tropical Medicine, Volume 8, pp. 37–44. doi: 10.2147/rrtm.s97309.

Manesh, A. et al. (2021) ‘Typhoid and paratyphoid fever: A clinical seminar’, Journal of Travel Medicine, 28(3), pp. 1–13. doi: 10.1093/jtm/taab012.

Masuet-Aumatell, C. and Atouguia, J. (2021) ‘Typhoid fever infection – Antibiotic resistance and vaccination strategies: A narrative review’, Travel Medicine and Infectious Disease, 40(December 2020), p. 101946. doi: 10.1016/j.tmaid.2020.101946.

Medise, B. E. et al. (2020) ‘A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report’, BMC Pediatrics, 20(1), pp. 1–8. doi: 10.1186/s12887-020-02375-4.

Meiring, J. E. et al. (2019) ‘Typhoid vaccine acceleration consortium Malawi: A Phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi’, Clinical Infectious Diseases, 68(Suppl 2), pp. S50–S58. doi: 10.1093/cid/ciy1103.

Milligan, R. et al. (2018) ‘Vaccines for preventing typhoid fever’, Cochrane Database of Systematic Reviews, 2018(5). doi: 10.1002/14651858.CD001261.pub4.

Mitra, M. et al. (2016) ‘Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyphTM) in Indian children: School based cluster randomized study’, Human Vaccines and Immunotherapeutics, 12(4), pp. 939–945. doi: 10.1080/21645515.2015.1117715.

Nampota-Nkomba, N. et al. (2022) ‘Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial’, The Lancet Global Health, 10(9), pp. e1326–e1335. doi: 10.1016/S2214-109X(22)00275-3.

Parker, A. R. et al. (2018) ‘Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity’, Journal of Immunological Methods, 459(April), pp. 1–10. doi: 10.1016/j.jim.2018.05.013.

Patel, P. D. et al. (2021) ‘Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children’, New England Journal of Medicine, 385(12), pp. 1104–1115. doi: 10.1056/nejmoa2035916.

Patel, P. D. et al. (2024) ‘Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children’, The Lancet, 403(10425), pp. 459–468. doi: 10.1016/S0140-6736(23)02031-7.

Tamrakar, D. et al. (2024) ‘Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers’, Human Vaccines and Immunotherapeutics, 20(1), pp. 1–9. doi: 10.1080/21645515.2023.2301631.

Vadrevu, K. M. et al. (2022) ‘Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children’, Human Vaccines and Immunotherapeutics, 18(7). doi: 10.1080/21645515.2022.2150030.

Yap, K. P. and Thong, K. L. (2017) ‘Salmonella Typhi genomics: envisaging the future of typhoid eradication’, Tropical Medicine and International Health, 22(8), pp. 918–925. doi: 10.1111/tmi.12899.

Zhu, H. et al. (2023) ‘Molecular correlates of vaccine-induced protection against typhoid fever’, Journal of Clinical Investigation, 133(16), pp. 1–17. doi: 10.1172/JCI169676.

Zuckerman, J. N., Hatz, C. and Kantele, A. (2017) ‘Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines’, Expert Review of Vaccines, 16(10), pp. 1029–1043. doi: 10.1080/14760584.2017.1374861.